Compare Regeneron Pharmaceuticals Inc (REGN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while BlackRock TCP Capital Corp trades at $3.2 (market cap $271.84M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 260.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (25.93%). Which is the better fit depends on your goals.
| REGN | TCPC | |
|---|---|---|
Market Cap | $70.79B | $271.84M |
Sector | Health | Financials |
52-Week High | $812.27 | $7.64 |
52-Week Low | $545.46 | $3.14 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | 25.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal from moving averages. The company reported negative revenue and net losses in 2025, though it beat Q1 2026 EPS estimates. A dividend of $0.17 per share is scheduled for June 30, 2026. Analyst consensus is mixed, with 31% buy ratings but 54% hold, reflecting caution amid financial challenges and an ongoing legal investigation into fiduciary duties.
The outlook remains cautious due to persistent negative earnings and revenue trends, with profitability metrics like ROE at -18.74% indicating weak shareholder returns. Risks include the shareholder lawsuit and competitive pressures in the BDC sector. Near-term focus is on the Q2 2026 earnings report due August 6, 2026, which could influence sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
